# Diagnostic algorithms for endoleaks

Prof. Fabio Verzini, MD, PhD, FEBVS

Vascular Surgery University of Perugia, Italy

# Conflicts of interest

#### Disclosure

Speaker name: Fabio Verzini

I have the following potential conflicts of interest to report:
 Receipt of grants/research support
 Receipt of honoraria and travel support

From: Cook, Gore, Medtronic

# Management of Abdominal Aortic Aneurysms Clinical Practice Guidelines of the European Society for Vascular Surgery

F.L. Moll<sup>a,\*</sup>, J.T. Powell<sup>b</sup>, G. Fraedrich<sup>c</sup>, F. Verzini<sup>d</sup>, S. Haulon<sup>e</sup>, M. Waltham<sup>f</sup>, J.A. van Herwaarden<sup>a</sup>, P.J.E. Holt<sup>g</sup>, J.W. van Keulen<sup>a,h</sup>, B. Rantner<sup>c</sup>, F.J.V. Schlösser<sup>h</sup>, F. Setacci<sup>i</sup>, J.-B. Ricco<sup>j</sup>





#### Follow-up compliance after endovascular abdominal aortic aneurysm repair in Medicare beneficiaries

Andres Schanzer, MD,<sup>a</sup> Louis M. Messina, MD,<sup>a</sup> Kaushik Ghosh, PhD,<sup>b</sup> Jessica P. Simons, MD, MPH,<sup>a</sup> William P. Robinson III, MD,<sup>a</sup> Francesco A. Aiello, MD,<sup>a</sup> Robert J. Goldberg, PhD,<sup>a</sup> and Allison B. Rosen, MD, MPH, ScD,<sup>a,b</sup> *Worcester and Cambridge, Mass* 

Among 19,962 patients who underwent EVAR, the incidence of loss to annual imaging follow-up at 5 years after EVAR was 50%.

JOURNAL OF VASCULAR SURGERY Volume 61, Number 1



Fig 2. Kaplan-Meier (*KM*) analysis of all patients who underwent endovascular aneurysm repair (EVAR) between 2001 and 2008 demonstrating the proportion of patients not lost to imaging follow-up.



Systematic review and meta-analysis of duplex ultrasonography, contrast-enhanced ultrasonography or computed tomography for surveillance after endovascular aneurysm repair

A. Karthikesalingam<sup>1</sup>, W. Al-Jundi<sup>2</sup>, D. Jackson<sup>3</sup>, J. R. Boyle<sup>4</sup>, J. D. Beard<sup>2</sup>, P. J. E. Holt<sup>1</sup> and M. M. Thompson<sup>1</sup>

# 25 studies = 3975 pts. DUS vs CT 11 studies= 961 pts. CEUS vs CT

Both CEUS and DUS were specific for detection of types 1 and 3 endoleak. Estimates of their sensitivity were uncertain but there was no evidence of a clinically important difference. DUS detects types 1 and 3 endoleak with sufficient accuracy for surveillance after EVAR





Surveillance instruments

CT superior to US :

- stent-graft position
- integrity
- sealing zones
- infection







#### Abdominal Aortic Endografting Beyond the Trials: A 15-Year Single-Center Experience Comparing Newer to Older Generation Stent-Grafts

Fabio Verzini, MD, PhD, FEBVS<sup>1</sup>; Giacomo Isernia, MD<sup>1</sup>; Paola De Rango, MD, PhD, FEBVS<sup>1</sup>; Gioele Simonte, MD<sup>1</sup>; Gianbattista Parlani, MD<sup>1</sup>; Diletta Loschi, MD<sup>1</sup>;

and Piergiorgio Cao, MD, FRCS<sup>2</sup>

J Endovasc Ther. 2014;21:439–447

1,412 EVAR

Old vs New- generation devices @ 7 years:

 Freedom from late conversion:
 96.1%vs. 89.1%, p<0.0001),</th>

 reintervention:
 83.6% vs. 74.2%; p=0.015

 AAA diameter growth >5mm:
 85.8% vs. 76.5%; p=0.022,

Were all significantly lower in the new generation group.

New generation device = negative independent predictor for		
reintervention	(HR 0.67, 95% Cl 0.49 - 0.93; p=0.015)	
aneurysm growth	(HR 0.63, 95% CI 0.45- 0.89; p=0.010.14)	









#### Fourteen-year outcomes of abdominal aortic endovascular repair with the Zenith stent graft



Fabio Verzini, MD, PhD, FEBVS,<sup>a</sup> Lydia Romano, MD,<sup>a</sup> Gianbattista Parlani, MD,<sup>a</sup> Giacomo Isernia, MD,<sup>a</sup> Gioele Simonte, MD,<sup>a</sup> Diletta Loschi, MD,<sup>a</sup> Massimo Lenti, MD, PhD,<sup>a</sup> and Piergiorgio Cao, MD, FRCS,<sup>b</sup> Perugia and Rome, Italy

# Aim of the study

Long term performance of the Zenith Cook endograft,

in a single center, tertiary care, University Hospital



# Long-Term Results

EVAR Failure: AAA related mortality, AAA rupture, AAA growth > 5 mm, re-intervention Cox regression analysis (backward stepwise)

AAA diameter Neck length <15 mm Age Smoking status Diabetes mellitus Hypertension Chronic pulmonary disease Coronary artery disease Renal disease Hyperlipidemia Peripheral arterial disease Anticoagulant therapy

Risk factor	HR	95 % CI
ASA 4	1.6	1-2.6
Type I or III Endoleak	10.8	7.2-16
Type II Endoleak	3.6	2.5-5.5



# Long-Term Results

Predictive factors of late reintervention: Cox regression analysis

Common iliac diameter >18 mm (HR 2.2, p<0.001)

Neck length Neck diameter AAA diameter Iliac Branch Endograft



## Clinical Significance of Type II Endoleak after Endovascular Repair of Abdominal Aortic Aneurysm

Dmitri V. Gelfand, MD,<sup>1</sup> Geoffrey H. White, MD,<sup>2</sup> and Samuel E. Wilson, MD,<sup>1</sup> Orange, California and Sydney, Australia

Ann Vasc Surg 2006; 20: 69-74

10 EVAR Trials (2000-2004) 2.617 patients



## Clinical Significance of Type II Endoleak after Endovascular Repair of Abdominal Aortic Aneurysm

Dmitri V. Gelfand, MD,<sup>1</sup> Geoffrey H. White, MD,<sup>2</sup> and Samuel E. Wilson, MD,<sup>1</sup> Orange, California and Sydney, Australia

Ann Vasc Surg 2006; 20: 69-74

# 10 EVAR Trials (2000-2004) 2.617 patients

Secondary Interventions0.3-30% (4.7%)Conversion10 (0.4%)Rupture0

Success of Secondary Interventions 11-100% (70%)

# Persistent type 2 endoleak after endovascular repair of abdominal aortic aneurysm is associated with adverse late outcomes

John E. Jones, MD, Marvin D. Atkins, MD, David C. Brewster, MD, Thomas K. Chung, MA, Christopher J. Kwolek, MD, Glenn M. LaMuraglia, MD, Thomas M. Hodgman, BA, and Richard P. Cambria, MD, Boston, Mass

873 patients

J Vasc Surg 2007;46:1-8

Aneurysm rupture. Aneurysm rupture four patients with an early type 2 endoleak. As

### Persistent Type II (3.8%) = significant predictor of rupture p=0.03

Freedom from Rupture

0.80 0

365





730

1095

Days Post EVAR

1460

1825

#### **Freedom from Rupture**

#### Type II endoleak after endovascular aneurysm repair

D. A. Sidloff<sup>1</sup>, P. W. Stather<sup>1</sup>, E. Choke<sup>1</sup>, M. J. Bown<sup>1,2</sup> and R. D. Sayers<sup>1</sup>

British Journal of Surgery 2013; 100: 1262–1270

21,744 pts; 1515 Type II	
Incidence of type II	10%
Spontaneous resolution	35%
Unsuccessful Tx (trans lumbar better than trans ar	28% terial)
Rupture / type II	0.9%

# Type II endoleak

**Early phase** 









+ poor distal sealing

Late phase







# Type II endoleak is an enigmatic and unpredictable marker of worse outcome after endovascular aneurysm repair

Enrico Cieri, MD, PhD,<sup>a</sup> Paola De Rango, MD, PhD,<sup>a</sup> Giacomo Isernia, MD,<sup>a</sup> Gioele Simonte, MD,<sup>a</sup> Andrea Ciucci, MD,<sup>a</sup> Gianbattista Parlani, MD,<sup>a</sup> Fabio Verzini, MD, PhD, FEBVS,<sup>a</sup> and Piergiorgio Cao, MD, FRCS,<sup>b</sup> *Perugia and Rome, Italy* 



## Treatment of Type 2 endoleak

#### Catheter embolization



F

# TC guided trans-lumbar AAA sac puncture





# Type II b endoleak



Peri-prosthetic (trans-sealing) lumbar embolization





# Safety of Chronic Anticoagulation Therapy After Endovascular Abdominal Aneurysm Repair (EVAR) CME $\stackrel{\sim}{\sim}$

P. De Rango <sup>a,\*</sup>, F. Verzini <sup>a</sup>, G. Parlani <sup>a</sup>, E. Cieri <sup>a</sup>, G. Simonte <sup>a</sup>, L. Farchioni <sup>a</sup>, G. Isernia <sup>a</sup>, P. Cao <sup>b</sup>

http://dx.doi.org/10.1016/j.ejvs.2013.12.009



N=1409, Anticoagulated = 103



# Perugia Diagnostic algorithm



# Conclusions

- Lifelong surveillance is mandatory for all
- AAA growth: surrogate of intra-sac pressure and rupture risk
- Persisting endoleaks are associated with higher risks of complications

# Conclusions

- Last generation endografts perform well
- Precise EVAR procedure inside
   IFU may suggest a "relaxed" f-u
   schedule
- Prompt re-intervention in case of impending failure due to the chronic dilating disease

